

Announcement Summary

# Entity name IMAGION BIOSYSTEMS LIMITED

# Announcement Type

New announcement

# Date of this announcement

Tuesday April 28, 2020

**The Proposed issue is: ③** A placement or other type of issue

## Total number of +securities proposed to be issued for a placement or other type of issue

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
IBXOA	OPTION EXPIRING 28-APR-2023 DEFERRED	45,635,111
IBX	ORDINARY FULLY PAID	45,635,111

## Proposed +issue date

Tuesday April 28, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

# 1.1 Name of +Entity

IMAGION BIOSYSTEMS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ACN

**Registration Number** 

616305027

1.3 ASX issuer code

IBX

# 1.4 The announcement is

Solution New announcement

1.5 Date of this announcement

Tuesday April 28, 2020

## 1.6 The Proposed issue is:

☑ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

C Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or	ted or ** Approval received/condition met?
+Security holder approval	Wednesday June 17, 2020	actual?	
		C Estimated	

### Comments

Under the Follow-On Placement the company has agreed to issue 45,635,111 Shares; and 45,635,111 bonus options (exercisable at 3 cents and expiring 28 April 2023) issued on a one for one basis. Of the Shares and Options issued under the Follow-on Placement, 45,635,111 Shares and 24,220,11 Options will be issued using the Company's existing capacity under Listing Rule 7.1. The issue of the remaining 21,415,000 Follow-on Placement New Options will be subject to shareholder approval at the 2020 AGM.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? ✓ Existing class Will the proposed issue of this +security include an offer of attaching +securities? ☑ Yes

Details of +securities proposed to be issued

**ASX +Security Code and Description** 

**IBX : ORDINARY FULLY PAID** 

Maximum Number of +securities proposed to be issued

45,635,111



## Purpose of the issue

The funds raised under the rights offer announced on 24 March 2020 have been expanded though the Follow-On Placement (Second supplementary prospectus announced 28 April 2020) to ensure, in light of market and business conditions related to the COVID-19 pandemic, that the Company has capital resources to maintain current Research and Development and manufacturing programs, and otherwise for general working capital purposes.

### Offer price details for retail security holders

In what currency is the cash	What is the issue price per	
consideration being paid?	+security?	
AUD - Australian Dollar	AUD 0.01000	

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes

**Oversubscription & Scale back details** 

May a scale back be applied to this event? 𝔅 No

#### Attaching +Security

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)? Security class

Attaching +Security - Existing class (additional +securities in a class that is already quoted or recorded by ASX)

#### Details of attaching +securities proposed to be issued

ASX +Security Code and Description

IBXOA : OPTION EXPIRING 28-APR-2023 DEFERRED

### Maximum Number of +securities proposed to be issued

45,635,111

Offer price details for retail security holders

In what currency is the cash consideration being paid? What is the issue price per +security?

**Oversubscription & Scale back details** 

May a scale back be applied to this event?  $\ensuremath{\mathfrak{C}}$  No



Part 7C - Timetable

**7C.1 Proposed +issue date** Tuesday April 28, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? ☑ Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

Wednesday June 17, 2020

7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?  $\textcircled{\sc S}$  No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? ☑ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?  $\ensuremath{\mathfrak{S}}$  No

Part 7E - Fees and expenses

#### 7E.1a Who is the lead manager/broker?

Mahe Capital

### 7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The fees payable to the lead manager (Mahe Capital) are outlined in section 5.3 of the Prospectus dated 25 March 2020, which is to be read in conjunction with the Second Supplementary Prospectus dated 28 April 2020

7E.2 Is the proposed issue to be underwritten? ☑ No



7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

The cost of the righst offer and Follow-On Placement outlined in section 2.6 of the Second Supplementary Prospectus dated 28 April 2020, which is to be read in conjunction with the Prospectus dated 25 March 2020

Part 7F - Further Information

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

N/A